Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SER-252

Small molecule · developed by Serina Therapeutics

Phase 1 Most advanced trial
SER Developer
1 Registered trials

What is SER-252?

SER-252 is a lyophilized formulation containing apomorphine, supplied as a sterile vial for reconstitution with an acetate-buffered, trehalose-containing diluent. It is being studied in advanced Parkinson's disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Neurology
Developer
Serina Therapeutics (SER)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07422675 Phase 1 PARKINSON DISEASE (Disorder) Recruiting SER

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Parkinson's DiseasePARKINSON DISEASE (Disorder)

More from Serina Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SER page.

Follow SER, the company behind SER-252

See SER's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SER catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.